Nonstimulant ADHD Medications
The FDA-approved nonstimulant medications for ADHD include atomoxetine, extended-release guanfacine, extended-release clonidine, and viloxazine extended-release, with atomoxetine being the most extensively studied and recommended as the primary nonstimulant option. 1, 2
FDA-Approved Nonstimulants
Norepinephrine Reuptake Inhibitors
Atomoxetine is the most established nonstimulant with extensive efficacy data across the lifespan 1, 3. It works by selectively inhibiting norepinephrine reuptake.
- Dosing: Available in 5,10,25, and 40 mg capsules
- Maximum dose: 100-120 mg/day (or 1.8 mg/kg in children) 4
- Titration: Start low and increase gradually to minimize gastrointestinal symptoms and somnolence 1
- Key adverse effects: Initial somnolence, GI symptoms (especially with rapid titration), decreased appetite, and growth delays in first 1-2 years that normalize by 2-3 years 1
- Black box warning: Increased suicidal thoughts (monitor closely) 1
- Rare but serious: Hepatitis (extremely rare) 1
Viloxazine extended-release is a newer norepinephrine reuptake inhibitor approved for children and adults in the US 5, 6. It has completed Phase 3 trials and offers an alternative noradrenergic option 6.
Alpha-2 Adrenergic Agonists
Extended-release guanfacine (GXR) and extended-release clonidine modulate noradrenergic activity through alpha-2 receptor agonism 1, 2.
- Guanfacine ER dosing: 1 and 3 mg tablets; maximum 6 mg/day 4
- Clonidine ER dosing: 0.1 mg tablets; maximum 0.4 mg/day 4
- Key adverse effects: Somnolence, dry mouth, dizziness, irritability, headache, bradycardia, hypotension, and abdominal pain 1
- Critical safety concern: These medications decrease heart rate and blood pressure 1
- Discontinuation warning: Must be tapered gradually—never stop abruptly due to risk of rebound hypertension 1
Cardiovascular Monitoring Requirements
Before initiating any nonstimulant, obtain:
- Personal history of cardiac symptoms
- Family history of sudden death, cardiovascular symptoms, Wolff-Parkinson-White syndrome, hypertrophic cardiomyopathy, and long QT syndrome
- If risk factors present: Obtain ECG and consider cardiology referral if abnormal 1
Monitor vital signs during treatment, particularly:
- Heart rate and blood pressure increases with atomoxetine
- Heart rate and blood pressure decreases with guanfacine and clonidine 1
Clinical Use Patterns
Atomoxetine is positioned as the primary nonstimulant alternative when stimulants are ineffective, not tolerated, or contraindicated 4, 3. In many Asian countries, it serves as second-line therapy after methylphenidate 4.
Alpha-2 agonists (guanfacine ER and clonidine ER) are the only nonstimulants with FDA approval for adjunctive use with stimulants 1. Limited evidence supports atomoxetine combination with stimulants on an off-label basis 1.
Treatment Approach
When stimulant therapy fails or causes limiting side effects, nonstimulants provide essential alternatives 2, 5. The choice depends on:
- Comorbid conditions: Alpha-2 agonists may benefit patients with tics or aggression
- Side effect profile tolerance: Atomoxetine if sedation is problematic; alpha-2 agonists if appetite suppression is concerning
- Cardiovascular status: Careful selection based on baseline heart rate and blood pressure
- Substance misuse risk: All nonstimulants lack abuse potential, making them preferable in at-risk populations 2
Common Pitfalls
- Rapid atomoxetine titration: Causes significant GI distress and somnolence—always start low and go slow 1
- Abrupt discontinuation of alpha-2 agonists: Can precipitate dangerous rebound hypertension—always taper 1
- Inadequate cardiovascular screening: Missing cardiac risk factors before initiation increases serious adverse event risk 1
- Expecting immediate response: Nonstimulants typically require several weeks to months for full effect, unlike stimulants